Should I buy or sell Sunshine Biopharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunshine Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SBFM shares. View SBFM analyst ratings or view top-rated stocks .

What is Sunshine Biopharma's stock price target for 2024?

1 brokerages have issued 1-year price targets for Sunshine Biopharma's shares. Their SBFM share price targets range from $2.60 to $2.60. On average, they predict the company's share price to reach $2.60 in the next twelve months. This suggests a possible upside of 1,109.3% from the stock's current price. View analysts price targets for SBFM or view top-rated stocks among Wall Street analysts .

How have SBFM shares performed in 2024?

Sunshine Biopharma's stock was trading at $0.2715 on January 1st, 2024. Since then, SBFM stock has decreased by 20.8% and is now trading at $0.2150. View the best growth stocks for 2024 here .

When is Sunshine Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024. View our SBFM earnings forecast .

How were Sunshine Biopharma's earnings last quarter?

Sunshine Biopharma, Inc. (NASDAQ:SBFM) issued its quarterly earnings data on Monday, November, 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. The business earned $5.96 million during the quarter. Sunshine Biopharma had a negative net margin of 131.52% and a negative trailing twelve-month return on equity of 124.32%.

How do I buy shares of Sunshine Biopharma?

Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SBFM

Sunshine Biopharma (SBFM) Stock Price, News & Analysis

$0.22

-0.02 (-6.60%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $0.21
▼
$0.24
50-Day Range: $0.22
▼
$0.29
52-Week Range: $0.21
▼
$1.40

Volume: 400,200 shs
Average Volume: 235,314 shs
Market Capitalization: $5.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.60

Get Sunshine Biopharma alerts:

Sunshine Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,109.3% Upside
$2.60 Price Target
Short Interest: Healthy
0.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.15 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Sunshine Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.60, Sunshine Biopharma has a forecasted upside of 1,109.3% from its current price of $0.22.
Amount of Analyst Coverage
Sunshine Biopharma has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.52% of the float of Sunshine Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Sunshine Biopharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sunshine Biopharma has recently decreased by 1.57%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Sunshine Biopharma does not currently pay a dividend.
Dividend Growth
Sunshine Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SBFM.

3.8

News and Social Media Coverage

News Sentiment
Sunshine Biopharma has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Sunshine Biopharma this week, compared to 0 articles on an average week.
MarketBeat Follows
2 people have added Sunshine Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
54.97% of the stock of Sunshine Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 9.79% of the stock of Sunshine Biopharma is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Sunshine Biopharma is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sunshine Biopharma is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sunshine Biopharma has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sunshine Biopharma Stock (NASDAQ:SBFM)

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in New York, New York.

SBFM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SBFM Stock News Headlines

January 23, 2024 | finance.yahoo.com

Analysts Are Optimistic We'll See A Profit From Sunshine Biopharma, Inc. (NASDAQ:SBFM)

November 28, 2023 | benzinga.com

Sunshine Biopharma Stock (NASDAQ:SBFM) Dividends: History, Yield and Dates

February 12, 2024 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

September 22, 2023 | finanznachrichten.de

Sunshine Biopharma, Inc.: Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

September 22, 2023 | finance.yahoo.com

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

September 14, 2023 | investopedia.com

What Are Sunshine Laws? Definition, Purpose, Examples

September 12, 2023 | finance.yahoo.com

It's Down 26% But Sunshine Biopharma, Inc. (NASDAQ:SBFM) Could Be Riskier Than It Looks

August 16, 2023 | finance.yahoo.com

When Will Sunshine Biopharma, Inc. (NASDAQ:SBFM) Breakeven?

February 12, 2024 | The Freeport Society (Ad)

Obama’s 2024 Confession

Barack Obama’s confession about the 2024 election just leaked online… In short, he’s worried Biden “could very well lose.” But before you think that means Trump will win… You should see the evidence I’ve found about an election shock that could come as soon as August 19th.

August 11, 2023 | finanznachrichten.de

Sunshine Biopharma Inc.: Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

August 11, 2023 | finance.yahoo.com

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

May 16, 2023 | finanznachrichten.de

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc.

May 16, 2023 | finance.yahoo.com

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

May 16, 2023 | finance.yahoo.com

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

May 12, 2023 | marketwatch.com

Sunshine Biopharma Shares Slide 22% Premarket on Private Placement >SBFM

May 12, 2023 | msn.com

Sunshine Biopharma to sell 5.95M units at $0.84 in private placement

May 12, 2023 | investorplace.com

SBFM Stock Alert: Why Sunshine Biopharma Is Down 28% Today

May 12, 2023 | finance.yahoo.com

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

May 11, 2023 | investorplace.com

SBFM Stock Alert: Why Sunshine Biopharma Is Up 80% Today

May 11, 2023 | technews.tmcnet.com

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

May 11, 2023 | finance.yahoo.com

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

April 5, 2023 | finance.yahoo.com

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

March 29, 2023 | cbsnews.com

First Alert Forecast: Sunshine returns Tuesday

February 28, 2023 | finanznachrichten.de

Financialnewsmedia.com: Coronavirus Vaccine Market To Surpass $95 Billion By 2028

February 10, 2023 | finance.yahoo.com

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

January 19, 2023 | finance.yahoo.com

Sunshine Biopharma Announces Share Repurchase Program

December 20, 2022 | finanznachrichten.de

Sunshine Biopharma Inc.: Sunshine Biopharma's Annual Letter to Shareholders

See More Headlines

Receive SBFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 2/11/2024
Next Earnings (Estimated): 4/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SBFM
CUSIP: N/A
CIK: 1402328
Web: www.sunshinebiopharma.com
Phone: (514) 426-6161
Fax: N/A
Employees: 46
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.60
High Stock Price Target: $2.60
Low Stock Price Target: $2.60
Potential Upside/Downside: +1,109.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-26,740,000.00
Net Margins: -131.52%
Pretax Margin: -129.51%
Return on Equity: -124.32%
Return on Assets: -95.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.00
Quick Ratio: 4.11

Sales & Book Value

Annual Sales: $4.35 million
Price / Sales: 1.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.96 per share
Price / Book: 0.22

Miscellaneous

Outstanding Shares: 25,680,000
Free Float: 11,563,000
Market Cap: $5.52 million
Optionable: Not Optionable
Beta: 1.62

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Steve N. Slilaty Ph.D. (Age 72)
Chairman, CEO & President
Comp: $430k
Mr. Camille Sebaaly (Age 65)
CFO & Secretary
Comp: $930k
Dr. Abderrazzak Merzouki (Age 60)
Chief Science Officer & Director
Comp: $545k
Mr. Marc Beaudoin (Age 57)
Chief Operating Officer
Mr. Malek Chamoun (Age 39)
Chief Development Officer
Mr. Robert G. Ferreira (Age 62)
President of Sunshine Bio Investments Inc

Key Competitors

View All Competitors

Institutional Ownership

Armistice Capital LLC
Sold 1,220,000 shares on 11/15/2023
Ownership: 3.793%

View All Institutional Transactions

SBFM Stock Analysis - Frequently Asked Questions

Should I buy or sell Sunshine Biopharma stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunshine Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SBFM shares.
View SBFM analyst ratings or view top-rated stocks.
What is Sunshine Biopharma's stock price target for 2024?: 1 brokerages have issued 1-year price targets for Sunshine Biopharma's shares. Their SBFM share price targets range from $2.60 to $2.60. On average, they predict the company's share price to reach $2.60 in the next twelve months. This suggests a possible upside of 1,109.3% from the stock's current price.
View analysts price targets for SBFM or view top-rated stocks among Wall Street analysts.
How have SBFM shares performed in 2024?: Sunshine Biopharma's stock was trading at $0.2715 on January 1st, 2024. Since then, SBFM stock has decreased by 20.8% and is now trading at $0.2150.
View the best growth stocks for 2024 here.
When is Sunshine Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our SBFM earnings forecast.

How were Sunshine Biopharma's earnings last quarter?: Sunshine Biopharma, Inc. (NASDAQ:SBFM) issued its quarterly earnings data on Monday, November, 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. The business earned $5.96 million during the quarter. Sunshine Biopharma had a negative net margin of 131.52% and a negative trailing twelve-month return on equity of 124.32%.
How do I buy shares of Sunshine Biopharma?: Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SBFM) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial